Ganirelix dosing & administration
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much Ganirelix do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
250 mcg
Frequency
Once daily during the mid-to-late follicular phase
Duration
Continued daily until the day of hCG administration (typically about 5-9 days)
FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].
Timing
Best time to take
Administer Ganirelix at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Ganirelix injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Ganirelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use Ganirelix?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store at 77°F (25°C); brief excursions between 59°F and 86°F (15–30°C) are permitted. [4] Protect from light. [4] Check the expiration date before use.
After reconstitution
Not applicable — ganirelix is a colorless, ready-to-use solution in a single-dose prefilled syringe; nothing is mixed. [4] Use each syringe once and discard any unused portion. [4] Air bubbles in the syringe are expected and do not need to be removed. [4]
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Ganirelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is Ganirelix safe?
Side effects
Commonly reported: Mild discomfort at treatment site, Injection site reactions (redness, bruising, swelling), Headaches, Abdominal pain, Pelvic discomfort, Nausea, Fatigue or dizziness
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ganirelix
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ganirelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GnRH antagonists (like cetrorelix) in the same cycle — Use with caution—discuss with your healthcare provider.
- Certain herbal supplements that affect hormones — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Mouanness M, et al. · 2025
Retrospective cohort of 269 IVF patients: oral elagolix 50 mg every other day (173) suppressed LH as well as daily injectable ganirelix or cetrorelix (96), with similar oocyte numbers, maturity, fertilization, blastocyst and euploidy rates; pregnancy outcomes were not assessed.
Glujovsky D, et al. · 2023
Cochrane review of 14 RCTs (2,643 women) on oral progestogens to prevent the LH surge: against GnRH antagonists there may be little or no difference in oocyte pick-up cancellation (low-certainty evidence), and live-birth effects are very uncertain.
Qi Q, et al. · 2023
Randomised trial in 156 women at high risk of OHSS after freeze-all: cetrorelix 0.25 mg plus letrozole and mifepristone lowered moderate/severe OHSS to 20.5% from 42.3% with mifepristone alone, with similar cumulative live birth rates (74.4% vs 76.9%). The antagonist used was cetrorelix, not ganirelix.
U.S. Food and Drug Administration · 2024
FDA label: ganirelix acetate 250 mcg is administered subcutaneously once daily during the mid-to-late follicular phase to inhibit premature LH surges in women undergoing controlled ovarian stimulation; continued daily until the day of hCG administration.
Head to head
Ganirelix compared
Want the full picture?
The complete Ganirelix research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.